© Reuters.
SCOTTSDALE, Ariz. – LifeStance Health, a major provider of outpatient mental healthcare, announced today the appointment of Dr. Teresa DeLuca to its board of directors. Dr. DeLuca, a psychiatrist with over two decades of leadership experience in the healthcare industry, joins LifeStance’s board with a background in both clinical practice and executive management.
Dr. DeLuca has held significant roles at several healthcare organizations, including Magellan Health (NASDAQ:), Humana (NYSE:), and Walgreens. Her expertise in healthcare operations and clinical management is expected to support LifeStance’s mission to deliver high-quality mental healthcare and expand patient access nationwide.
Ken Burdick, Chairman and CEO of LifeStance, expressed confidence that Dr. DeLuca’s skills will enhance the board’s capabilities as the company continues to address the growing mental health crisis in the country. Dr. DeLuca herself highlighted LifeStance’s role in providing comprehensive mental healthcare and expressed enthusiasm for contributing to its mission.
Previously, Dr. DeLuca served as Managing Director at Columbia University’s NY Life Science Venture, focusing on the commercialization of early-stage life sciences technologies. She also spearheaded innovative healthcare products at Magellan Health as Chief Medical Officer, where she integrated behavioral health data with pharmacy claims and clinical management.
Her experience extends to her tenure as SVP at Humana, overseeing sales, operations, and clinical management.
Dr. DeLuca’s educational background includes an MBA from Drexel University’s LeBow College of Business and a medical degree from Thomas Jefferson University. She is also a member of the board of directors for Surgery Partners (NASDAQ:) and Rejuveron.
LifeStance Health, founded in 2017 and listed on NASDAQ (NASDAQ: LFST), operates over 550 centers across 33 states, employing approximately 6,600 mental health professionals. The company’s approach to mental healthcare focuses on improving access and personalization for patients of all ages.
This news is based on a press release statement from LifeStance Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
This story originally appeared on Investing
